Screening for hepatitis B carriers: A perspective from New Zealand

Australian and New Zealand Journal of Medicine

Volumn 27, Issue 6, 1997, Pages 698-705

  Paul, C ^a,c   Thomas, M ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; NEW ZEALAND; REVIEW; VIRUS CARRIER; VIRUS TRANSMISSION;

EID: 0031415936     PISSN: 00048291     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1445-5994.1997.tb01001.x     Document Type: Review

References (66)

1. Working party on hepatitis B. Screening and hepatitis B infection in New Zealand. Report to the Director General of Health, 1994. (Unpublished report.)
2. Mulley AG, Silverstein MD, Dienstag JL. Indications for the use of hepatitis B vaccine, based on cost-effectiveness analysis. N Engl J Med 1982; 307: 644-52.
3. Kwan-Gett TSC, Whitaker RC, Kemper KJ. A cost-effectiveness analysis of prevaccination testing for hepatitis B in adolescents and preadolescents. Arch Pediatr Adolesc Med 1994; 148: 915-20.
4. Mangtani P, Hall AJ, Normand CEM. Hepatitis B vaccination: the cost effectiveness of alternative strategies in England and Wales. J Epidemiol Community Health 1995; 49: 238-44.
5. Hermon YE, Mushahwar IK, Tobias MI. Hepatitis B infection in New Zealand children. NZ Med J 1984; 97: 887-9.
6. Tobias MI, Miller JA, Clements CJ, Patel AC. Hepatitis B in New Zealand children: the 1985 national immunization survey. NZ Med J 1987; 100: 203-6.
7. Department of Health. Immunization handbook. Wellington: Department of Health, 1993.
8. Lyttle H. New Zealand 1992 sexual health clinic statistics. Venereology 1993; 6: 112-3.
9. Holland P. Hepatitis B surface antigen and antibody (HBsAg/anti HBs). In: Gerety RJ (Ed.). Hepatitis B. Orlando, Fla: Academy Press, 1985.
10. CDC. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee. MMWR 1990; 39 (No. RR-2).
11. Moyes CD (Ed.). Management of hepatitis B carriers. Whakatane: Hepatitis Research Unit, 1991.
12. Edwards V. Hepatitis B - New Zealand's third world shame. GP Weekly 1995; February 1: 16.
13. McLeod D, O'Hallahan J, Durham G. The follow-up of hepatitis B positive patients at Hutt Hospital. Communicable Disease New Zealand 1993; 93: 49-54.
14. US Preventive Services Task Force. Screening for hepatitis B. In: Fisher M (Ed.). Guide to clinical preventive services. Report of the US Preventive Services Task Force. Baltimore: Williams and Wilkins, 1989.
15. Faculty of Public Health Medicine: Committee on health promotion. Hepatitis B. Guidelines for health promotion No. 35. London: Faculty of Public Health Medicine, 1993.
16. McMahon BJ, Wainwright RW, Lanier AP. The Alaska native HCC screening program: a population-based screening program for hepatocellular carcinoma. In: Tabor E (Ed.). Etiology, pathology and treatment of hepatocellular carcinoma in North America. Advances in Applied Biotechnology Series 1991; 13: 231-41.
17. Mima S, Sekiya C, Kanagawa H et al. Mass screening for hepatocellular carcinoma: Experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994; 9: 361-5.
18. Tang Z-Y, Yu Y-Q, Zhou X-D et al. Surgery of small hepatocellular carcinoma. Analysis of 144 cases. Cancer 1989; 64: 536-41.
19. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22: 432-8.
20. McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991; 83: 916-9.
21. Wong VCW, Ip HMH, Reesink HW et al. Prevention of the HBsAg carrier state in newborn infants of mothers who are chronic carriers of HBsAg and HBeAg by administration of hepatitis B vaccine and hepatitis B immunoglobulin. Lancet 1984; i: 921-6.
22. Stevens CE, Taylor PE, Tong MJ et al. Yeast-recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA 1987; 257: 2612-6.
23. Jonas MM, Schiff ER, O'Sullivan MJ et al. Failure of Centers for Disease Control criteria to identity hepatitis B infection in a large municipal obstetrical population. Ann Intern Med 1987; 107: 335-7.
24. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. JAMA 1988; 259: 365-9.
25. Cairns JA, Shackley P. Assessing value for money in medical screening. J Med Screening 1994; 1: 39-44.
26. Margolis HS, Alter MJ, Hadler SC. Hepatitis B: evolving epidemiology and implications for control. Semin Liver Disease 1991; 11: 84-92.
27. Szmuness W, Stevens CE, Harley EJ et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high risk population in the United States. N Engl J Med 1980; 303: 833-41.
28. Martineau TM. Psychological costs of screening. Br Med J 1989; 299: 527.
29. Blumberg BS, Fox RC. The Daedalus effect: changes in ethical questions relating to hepatitis B virus. Ann Intern Med 1985; 102: 390-4.
30. Martineau TM. Screening in practice. Reducing the psychological costs. Br Med J 1990; 301: 26-8.
31. McMahon BJ, Alberts SR, Wainwright RB, Bulkow L, Lanier AP. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-4.
32. Weissberg JI, Andres LL, Smith CI et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med 1984; 101: 613-8.
33. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664-75.
34. DiBisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. Hepatocellular carcinoma. Ann Intern Med 1988; 108: 390-401.
35. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alpha-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990; 323: 295-301.
36. Tine F, Liberati A, Craxi A, Almasio P, Pagliaro L. Interferon treatment in patients with chronic hepatitis B: a meta-analysis of the published literature. J Hepatol 1993; 18: 154-62.
37. Korenman J, Baker B, Waggoner J, Everhart JE, DiBisceglie AM, Hoofnagle JH. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-34.
38. Garcia de Ancos JL, Roberts JA, Dusheiko GM. An economic evaluation of the costs of alpha-interferon treatment of chronic active hepatitis due to hepatitis B or C virus. J Hepatol 1990; 11: S11-S18.
39. Colombo M. Hepatocellular carcinoma. J Hepatol 1992; 15: 225-36.
40. Wands JR, Blum HE. Primary hepatocellular carcinoma. N Engl J Med 1991; 325: 729-31.
41. Levin B, Amos C. Therapy of unresectable hepatocellular carcinoma. N Engl J Med 1995; 332: 1294-6.
42. Ebara M, Ohto M, Shinagawa T et al. Natural history of minute hepatocellular carcinoma smaller than three centimetres complicating cirrhosis. A study in 22 patients. Gastroenterology 1986; 90: 289-98.
43. Shinagawa T, Ohto M, Kimura K et al. Diagnosis and clinical features of small hepatocellular carcinoma with emphasis on the utility of real-time ultrasonography. A study in 51 patients. Gastroenterology 1984; 86: 495-502.
44. Maringhini A, Cottone M, Sciarrino E et al. Ultrasonography and alpha-fetoprotein in diagnosis of hepatocellular carcinoma in cirrhosis. Dig Dis Sci 1988; 33: 47-51.
45. Lee H-S, Chung YH, Kim CY. Specificities of serum alpha fetoprotein in HBsAg+ and HBsAg- patients in the diagnosis of hepatocellular carcinoma. Hepatology 1991; 14: 68-72.
46. Kang JY, Lee TP, Yap I, Lun KC. Analysis of cost-effectiveness of different strategies for hepatocellular carcinoma screening in hepatitis B virus carriers. J Gastroenterol Hepatol 1992; 7: 463-8.
47. Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991; 325: 675-80.
48. Sheu J-C, Sung J-L, Chen D-S et al. Early detection of hepatocellular carcinoma by real-time ultrasonography. A prospective study. Cancer 1985; 56: 660-6.
49. Morrison AS. Screening in chronic disease. 2nd edn. New York: Oxford University Press, 1992: 3-20.
50. London WT, Chen G-C, Shen F-M, Zhou T, Evans A. Early detection of hepatocellular carcinoma in China and United States. Abstract. Proceedings of the Hepatitis Workshop. Whakatane: Hepatitis Foundation, 1993.
51. Sampliner RE. Follow-up and management of hepatitis B carriers. In: Gerety RJ (Ed.). Hepatitis B. Orlando, Florida: Academic Press, 1985: 155-72.
52. Gerety RJ, Tabor E. The epidemiology of hepatitis B. In: Gerety RJ (Ed.). Hepatitis B. Orlando, Florida: Academic Press, 1985: 77-92.
53. Miller JA, Hermon YE. Hepatitis B in pregnant women. NZ Med J 1984; 97: 461.
54. Wilson N. The epidemiology and control of hepatitis B in New Zealand. MPH thesis. Dunedin: University of Otago, 1993.
55. Milne A, Allwood GK, Moyes CD, Pearce NE. Prevalence of hepatitis B infection in a multi-racial New Zealand community. NZ Med J 1985; 98: 529-32.
56. Schreeder MT, Bender TR, McMahon BJ et al. Prevalence of hepatitis B in selected Alaskan Eskimo villages. Am J Epidemiol 1983; 118: 543-9.
57. McMahon BJ, Rhoades ER, Heyward WL et al. A comprehensive programme to reduce the incidence of hepatitis B virus infection and its sequelae in Alaskan Natives. Lancet 1987; ii: 1134-6.
58. Pearce N, Milne A, Moyes C. Hepatitis B virus: the importance of age at infection. NZ Med J 1988; 101: 788-90.
59. New Zealand Department of Health. Hepatitis B. Circular letter to medical practitioners 1/91, 1991.
60. Higginson J, Muir CS, Munoz N (Eds.). Human cancer: epidemiology and environmental causes. Cambridge Monographs in Cancer Research. Cambridge: Cambridge University Press, 1992: 296-310.
61. Tukuitonga CF, Solomon N, Stewart A. Incidence of cancer among Pacific Island people in New Zealand. NZ Med J 1992; 105: 463-6.
62. Mosley JW. The HBV carrier - a new kind of leper. N Engl J Med 1975; 292: 477-8.
63. NZ Government. Human Rights Act 1993. Wellington: NZ Government, 1993.
64. Public Health Commission. He Matariki: a strategic plan for Maori public health. Wellington: Public Health Commission, 1995.
65. Maori Affairs Committee. Hepatitis B screening programme for Maori. Wellington: House of Representatives, 1995.
66. CDC. US Public Health Service recommendations for Human Immunodeficiency Virus counseling and voluntary testing for pregnant women. MMWR 1995; 44 (No. RR-7).